Kidney Transplant Rejection - Pipeline Review, H1 2018

  • ID: 4521341
  • Report
  • 165 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Bioverativ Inc
  • Gilead Sciences Inc
  • Idogen AB
  • Kyowa Hakko Kirin Co Ltd
  • Opsona Therapeutics Ltd
  • MORE
Kidney Transplant Rejection - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

Report Highlights:

This latest pipeline guide Kidney Transplant Rejection - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 10, 10, 16 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Bioverativ Inc
  • Gilead Sciences Inc
  • Idogen AB
  • Kyowa Hakko Kirin Co Ltd
  • Opsona Therapeutics Ltd
  • MORE
Introduction

Kidney Transplant Rejection - Overview

Kidney Transplant Rejection - Therapeutics Development

Kidney Transplant Rejection - Therapeutics Assessment

Kidney Transplant Rejection - Companies Involved in Therapeutics Development

Kidney Transplant Rejection - Drug Profiles

Kidney Transplant Rejection - Dormant Projects

Kidney Transplant Rejection - Discontinued Products

Kidney Transplant Rejection - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Kidney Transplant Rejection - Pipeline by Amgen Inc, H1 2018

Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp, H1 2018

Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc, H1 2018

Kidney Transplant Rejection - Pipeline by Balmes Transplantation SAS, H1 2018

Kidney Transplant Rejection - Pipeline by Bioverativ Inc, H1 2018

Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc, H1 2018

Kidney Transplant Rejection - Pipeline by CSL Ltd, H1 2018

Kidney Transplant Rejection - Pipeline by Gilead Sciences Inc, H1 2018

Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H1 2018

Kidney Transplant Rejection - Pipeline by Hansa Medical AB, H1 2018

Kidney Transplant Rejection - Pipeline by Idogen AB, H1 2018

Kidney Transplant Rejection - Pipeline by ITB-Med AB, H1 2018

Kidney Transplant Rejection - Pipeline by Johnson & Johnson, H1 2018

Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018

Kidney Transplant Rejection - Pipeline by Magnus Life Ltd, H1 2018

Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG, H1 2018

Kidney Transplant Rejection - Pipeline by Novartis AG, H1 2018

Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd, H1 2018

Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd, H1 2018

Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC, H1 2018

Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H1 2018

Kidney Transplant Rejection - Pipeline by Shire Plc, H1 2018

Kidney Transplant Rejection - Pipeline by TolerogenixX GmbH, H1 2018

Kidney Transplant Rejection - Pipeline by TxCell SA, H1 2018

Kidney Transplant Rejection - Dormant Projects, H1 2018

Kidney Transplant Rejection - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Angion Biomedica Corp
  • Astellas Pharma Inc
  • Balmes Transplantation SAS
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • CSL Ltd
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Hansa Medical AB
  • Idogen AB
  • ITB-Med AB
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co Ltd
  • Magnus Life Ltd
  • Noorik Biopharmaceuticals AG
  • Novartis AG
  • Opsona Therapeutics Ltd
  • Pharmicell Co Ltd
  • Prolong Pharmaceuticals LLC
  • Quark Pharmaceuticals Inc
  • Shire Plc
  • TolerogenixX GmbH
  • TxCell SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll